Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Apr 012012

The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.    

Senesco Technologies has updated information on its web site (https://www.senesco.com/; obtained on 3-18-12). As a matter of disclosure : The author continues to be a current shareholder in the company.

In the website section,”About Us”, the following designated “Profile” is presented :

 “The company’s platform technology is based on the discovery that eIF5A (Factor 5A), a gene that is highly conserved from plants to people, has the ability to regulate programmed cell death, also known as apoptosis, and cell survival by controlling the expression of pro-apoptotic and anti-apoptotic proteins.

In order to modulate apoptosis, based on recent discoveries in gene regulation Senesco has developed SNS01-T, which has two active components, an siRNA (hotlink needed) and a DNA plasmid (hotlink needed), that modulate Factor 5A and an inactive component, polyethylenimine, that serves to assemble the active molecules into nanoparticles to facilitate delivery to the target cells. The siRNA turns down production of the Factor 5A pro-survival protein and sensitizes the cancer cells to death stimuli while the DNA plasmid, selectively turns on the production of a stable Factor 5A protein with a single amino acid substitution, which actively triggers cancer cell death. Polyethylenimine is a polycationic carrier that protects the DNA plasmid/siRNA combination from degradation in the blood stream until it can reach the tumor cells and release its active ingredients.

Senesco has initated initiated a clinical program in multiple myeloma patients with its lead therapeutic candidate SNS01-T, which has been granted orphan drug status by the US FDA. Senesco is building its portfolio by investigating other potential eIF5A applications in cancer, inflammation and ischemia.”

The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.                                    © 2012 The Hygiology Post